The adult mammalian heart lacks regenerative capacity and heals through activation of an inflammatory cascade that leads to the formation of a collagen-based scar. Although scar formation is important to preserve the structural integrity of the ventricle, unrestrained inflammation and excessive fibrosis have been implicated in the pathogenesis of adverse post-infarction remodeling and heart failure. Interstitial cells play a crucial role in the regulation of cardiac repair. Although recent studies have explored the role of fibroblasts and immune cells, the cardiac pericytes have been largely ignored by investigators interested in myocardial biology. This review manuscript discusses the role of pericytes in the regulation of inflammation, fibrosis and angiogenesis following myocardial infarction. During the inflammatory phase of infarct healing, pericytes may regulate microvascular permeability and may play an important role in leukocyte trafficking. Moreover, pericyte activation through Toll-like receptor-mediated pathways may stimulate cytokine and chemokine synthesis. During the proliferative phase, pericytes may be involved in angiogenesis and fibrosis. To what extent pericyte to fibroblast conversion and pericytemediated growth factor synthesis contribute to the myocardial fibrotic response remains unknown. During the maturation phase of infarct healing, coating of infarct neovessels with pericytes plays an important role in scar stabilization. Implementation of therapeutic approaches targeting pericytes in the infarcted and remodeling heart remains challenging, due to the lack of systematic characterization of myocardial pericytes, their phenotypic heterogeneity and the limited knowledge on their functional role.
Introduction
Pericytes are vascular mural cells that are embedded within the microvascular basement membrane, enwrapping capillaries, venules and terminal arterioles (1, 2, 3, 4) . In contrast, larger vessels, such as arteries and veins, are coated by vascular smooth muscle cells. Pericytes are ubiquitously found in all organs and contribute to vascular maturation and stability, by regulating capillary permeability and by restraining endothelial cell proliferation. In addition to their role in microvascular homeostasis, a growing body of evidence implicates pericytes in a wide range of cellular responses, a significant proportion of non-endothelial, nonhematopoietic interstitial myocardial cells (14, 13) . Following myocardial infarction, sudden loss of up to a billion cardiomyocytes releases danger signals, activating an intense inflammatory response that serves to clear the wound from dead cells and extracellular matrix debris (15) . Because the adult mammalian heart has negligible regenerative capacity, interstitial cell populations play a critical role in repair of the infarcted heart. However, excessive, prolonged or unrestrained activation of matrixproducing interstitial cells may contribute to adverse remodeling and to the pathogenesis of post-infarction heart failure (16) . Considering their abundance, phenotypic plasticity and functional diversity, pericytes may be critically involved in regulating inflammatory, fibrotic, angiogenic and reparative responses following myocardial infarction. The current review manuscript discusses our current knowledge on the role of pericytes in injury, repair and remodeling of the infarcted heart.
Pericytes in the normal myocardium
The adult mammalian heart contains abundant interstitial cells, including fibroblasts, pericytes and macrophages (13, 14) . Early ultrastructural studies have identified a large population of pericytes in normal adult mammalian hearts and suggested that these cells form an incomplete layer around the microvascular endothelium (17, 18) . Due to the lack of specific and reliable markers to identify pericytes, and to differentiate them from other interstitial cells, studies systematically characterizing myocardial pericyte populations are lacking. Several molecular markers have been used to identify cardiac pericytes, including the proteoglycan neural/glial2 (NG2), platelet-derived growth factor β (PDGFRβ), CD146 and CD73, α-smooth muscle actin (SMA), desmin, nestin, alkaline phosphatase and the zinc finger protein Glioma-associated oncogene protein 1 (Gli1) (8, 19) . Information on the specificity and sensitivity of these markers for detection of myocardial pericytes is limited and sometimes conflicting. Methodological differences between studies, species-specific properties of pericyte populations and differences in the definition of pericytes may account for conflicting findings.
Although NG2 is expressed by cardiomyocytes in embryonic hearts (20) , in the adult mammalian myocardium NG2 expression specifically labels mural cells, both pericytes and vascular smooth muscle cells (Fig. 1) . In normal hearts, PDGFRβ expression also seems to be restricted to vascular mural cells (21) . In contrast, α-SMA expression marks vascular smooth muscle cells and not microvascular pericytes, whereas desmin is not expressed by cardiac pericytes (19) . A growing body of evidence suggests that cardiac pericytes exhibit significant heterogeneity. In rat hearts, the majority of pericytes were found to co-express PDGFRβ and NG2, while a much smaller subset (around 6%) of PDGFRβ+ cells were NG2 negative (22) . Studies in mice classified pericytes on the basis of expression of the intermediate filament protein, nestin. Nestin-positive and nestin-negative NG2-expressing pericytes were noted in normal hearts; however, only nestin-expressing cells exhibited significant expansion following infarction (23) .
The functional role of pericytes in cardiac homeostasis remains poorly understood. Pericytes play an important role in vascular patterning and maturation (24) , restrain endothelial cell proliferation and control microvascular permeability (25) . Although experiments depleting myocardial pericytes in adult animals have not been performed, several lines of evidence suggest that cardiac pericytes may support similar functions in the myocardium. First, mice lacking PDGF-B or PDGFRβ exhibit pericyte loss, associated with perturbed vascular development and formation of microaneurysms in many organs, including the heart (26) . Second, administration of tyrosine kinase inhibitors (such as the anticancer agent, sunitinib) that target PDGF receptors induces cardiotoxicity, associated with pericyte loss and microvascular dysfunction (27) . Third, mice with endothelial cell-specific overexpression of angiopoietin-2 have marked loss of capillary-associated pericytes, associated with cardiomyopathy (28) . It should be emphasized that whether pericyte loss plays a causative role in the myocardial pathology associated with PDGF-B/ PDGFRβ disruption or angiopoietin overexpression was not documented. Thus, these experimental studies provide only supportive evidence on the role of cardiac pericytes in homeostasis. Fourth, conditions characterized by perturbed pericyte function, such as diabetes are associated with myocardial capillary rarefaction that may limit the functional reserve of the heart under conditions of stress (29, 30) .
Pericytes in infarcted hearts
The phases of cardiac repair: from inflammation to fibrosis
In adult mammals, myocardial infarction results in sudden loss of up to a billion cardiomyocytes, overwhelming the negligible regenerative capacity of the heart. Thus, the infarcted myocardium heals through a well-orchestrated inflammatory/reparative response that ultimately leads to formation of a collagen-based scar (15, 31) . The cell biological response following myocardial infarction can be divided into three distinct, but overlapping phases: the inflammatory, the proliferative and the maturation phase.
During the early inflammatory phase, release of danger signals from dying cardiomyocytes and protease-induced generation of matrikines, matrix fragments with proinflammatory properties, activates Toll-like receptor signaling pathways in cardiomyocytes, interstitial cells and immune cells and inducing cytokine and chemokine expression (32) . Recruitment of abundant and diverse leukocyte populations in the infarcted heart clears the wound from dead cells and matrix fragments, while setting the stage for expansion of reparative cells through macrophage and lymphocyte-mediated secretion of growth factors (33) . Induction of anti-inflammatory signals, such as TGF-βs and IL-10, not only suppresses inflammation, but also activates fibroblasts and vascular cells (34, 35, 36) leading to the proliferative phase of infarct healing. Conversion of fibroblasts to myofibroblasts is the dominant cellular event during the proliferative phase of infarct healing (37, 38) . Activated myofibroblasts secrete both structural and matricellular extracellular matrix proteins, preserving the structural integrity of the ventricle and protecting from cardiac rupture (36, 39) . The maturation phase follows, as myofibroblasts become quiescent (40) and a dense collagenous network comprising cross-linked collagen is formed. As the scar matures, the non-infarcted segments remodel, exhibiting hypertrophy and interstitial fibrosis and may develop worsening dysfunction. Chronic remodeling of noninfarcted segments may involve sustained neurohumoral activation and the effects of pressure and volume loads, due to the loss of contractile muscle in the infarcted area, the elevated filling pressures and the progressive chamber dilation following infarction (31) .
As the heart transitions through the phases of repair and remodeling following infarction, cardiac pericytes exhibit dynamic functional and phenotypic alterations in response to the dramatic microenvironmental changes (Fig. 2) . Unfortunately, myocardial biologists have ignored the pericytes; for this reason, information on their functional role in cardiac injury and repair remains extremely limited.
Pericytes in acute myocardial ischemia and during the inflammatory phase of cardiac repair
Induction of pro-inflammatory cytokines following infarction increases microvascular permeability accentuating cardiac injury. Evidence derived from experimental models of reperfused myocardial infarction suggests an important role for pericytes in regulation of capillary barriers. Although the molecular signals involved in pericyte activation remain poorly characterized, published evidence suggests an important role for nerve growth factor (NGF) and angiopoietin-2 in accentuation of pericyte-driven vascular hyperpermeability. Pro-NGF, an injury-induced cytokine, is rapidly upregulated in cardiomyocytes following myocardial ischemia and reperfusion and activates the p75 receptor in pericytes promoting microvascular dysfunction that extends the area of infarction (41) . On the other hand, angiopoietin-2 is released by ischemic endothelial cells and promotes pericyte detachment, increasing microvascular permeability (42) .
In addition to their effects in regulation of microvascular function, pericytes may actively participate in the post-infarction inflammatory response by producing pro-inflammatory cytokines and chemokines. Danger signals released following infarction may activate innate immune signaling cascades in pericytes promoting a pro-inflammatory phenotype. Brain and lung pericytes have been demonstrated to express TLRs and activate inflammatory cascades in response to stimulation with TLR ligands (43, 44) . Stark and coworkers (45) 
that cytokine-or lipopolysaccharide-stimulated human pericytes express TLR2 and TLR4, the G-protein-coupled receptor N-formyl peptide receptor (FPR) 2, tumor necrosis factor receptor 1 (TNFR1) and the cytoplasmic receptor NLR family pyrin domain-containing 3 (NLRP3). The significance of pro-inflammatory pericyte activation in myocardial infarction remains unknown. Whether pericytes in the infarcted myocardium can respond to the release of alarmins by dying cardiomyocytes has not been investigated. Considering the wellestablished contributions of other cell types as sources of inflammatory cytokines and chemokines (including endothelial cells (46) , fibroblasts (47), macrophages (48) and cardiomyocytes (49, 50) ), the relative role of pericytes in secretion of pro-inflammatory mediators remains unclear.
Despite the absence of direct evidence in models of myocardial injury, pericytes may serve as critical regulators of leukocyte transendothelial trafficking cascades. Recruitment of neutrophils, monocytes and lymphocytes in sites of injury is driven by chemokinedependent adhesive interactions between endothelial cells and circulating leukocytes (51) . Migrating neutrophils and monocytes are found to be polarized when in close vicinity of pericytes, suggesting a role for pericyte-derived factors to drive chemotaxis of leukocytes. Pericytes may contribute to leukocyte chemotaxis by releasing chemokines and by 'instructing' leukocytes exiting through venules with pattern-recognition and motility programs (45) . Intravital microscopy experiments in cremaster muscle demonstrated that cytokine-mediated pericyte activation triggers transition to an 'inflammatory phenotype', characterized by the expression of adhesion molecules and chemoattractant mediators that provide molecular cues to transmigrating leukocytes. Moreover, inflammatory activation causes shape changes in pericytes, promoting enlargement of gaps between adjacent pericytes. Thus, leukocytes use the enlarged gaps as exit points during transmigration into the injured tissue (52) . Whether alterations in the morphology and adhesive properties of pericytes are involved in leukocyte trafficking in infarcted hearts remains unknown.
In addition to their role in inflammation and in leukocyte trafficking, pericytes may also play an important role in degradation of the pericellular extracellular matrix. Pericyte-mediated breakdown of the basement membrane and detachment from endothelial cells is an important early step in angiogenesis (53) . Although other cardiac interstitial cells, such as fibroblasts, acquire a matrixdegrading phenotype during the early inflammatory phase of healing, producing matrix metalloproteinases in response to stimulation with IL-1β (54), whether cardiac pericytes also participate in matrix degradation remains unknown.
Pericytes have also been implicated in the pathogenesis of the 'no-reflow phenomenon'. Coronary no-reflow occurs when the myocardium fails to perfuse despite restoration of coronary flow (55) . In experimental models
Figure 2
The role of endogenous pericytes in myocardial infarction. The adult mammalian heart lacks regenerative capacity and heals through formation of a collagen-based scar. The reparative response can be divided into three distinct, but overlapping phases: the inflammatory phase, the proliferative phase and the maturation phase. The normal myocardium contains a large population of pericytes with peri-endothelial location. During the inflammatory phase, release of alarmins from dying cells may activate TLR-mediated pathways in pericytes, stimulating cytokine and chemokine secretion. Moreover, pericytes may produce matrix metalloproteinases, thus degrading the microvascular basement membrane and stimulating an angiogenic response. Formation of gaps between pericytes in the pro-inflammatory environment of the infarct may be required for leukocyte extravasation. Pericytes also regulate microvascular function. Constriction of pericytes in the ischemic and reperfused myocardium has been implicated in the pathogenesis of 'no-reflow'. During the proliferative phase, pericytes activated by growth factors may regulate angiogenesis and fibrosis. To what extent pericyte to fibroblast conversion contributes to the expansion of myofibroblasts in healing infarcts remains unclear. Pericytes may also produce angiogenic and fibrogenic growth factors. During the maturation phase infarct neovessels recruit mural cells (both pericytes and vascular smooth muscle cells) through PDGFRβ-dependent pathways. Acquisition of a mural cell coat may be important to stabilize the infarct vasculature and to protect the infarcted heart from sustained inflammation.
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Pericytes in myocardial infarction Q1 H27 1:1 of myocardial ischemia/reperfusion, endothelial injury and leukocyte plugging may cause microvessel occlusion, accentuating ischemic injury. In human patients, thrombi and atherosclerotic debris may embolize microvessels further reducing microvascular flow (56) . A recently published study in a rat model of myocardial ischemia and reperfusion suggested that pericyte constriction contributes to the 'no-reflow phenomenon' by causing microvascular obstruction (22, 57) . NG2-fluorescent labeling revealed that most of the blocked sites were spatially associated with pericytes. Coronary capillary lumen diameter was reduced by 37% at sites of pericyte juxtaposition upon ischemia, when compared to shamoperated hearts, suggesting a possible role for pericytes in coronary no-reflow phenomenon. Pericyte relaxation through administration of adenosine markedly increased perfusion in the ischemic and reperfused myocardium (22) . Despite the limitations of the study, related to the broad effects of adenosine on many cell types, these intriguing observations support a potential role for pericyte constriction in mediating persistent reduction of microvascular flow following ischemia, despite reperfusion of the culprit vessel.
Pericytes during the proliferative phase of infarct healing: a role in fibrosis?
Transition to the proliferative phase of cardiac repair is preceded by suppression of pro-inflammatory signaling cascades (58) . As pro-inflammatory signaling is attenuated, fibroblasts become activated and acquire a myofibroblast phenotype, incorporating α-SMA into cytoskeletal stress fibers and producing large amounts of extracellular matrix proteins (37, 59, 60) . Myofibroblast activation is accompanied by an intense angiogenic response, presumably to support the metabolically active hypercellular wound with oxygen and nutrients (61) . The potential role of pericytes in the proliferative phase of repair is poorly supported by experimental evidence. However, considering their abundance, phenotypic plasticity and responsiveness to growth factors and cytokines, pericytes may contribute to several of the cellular events associated with the proliferative phase of cardiac repair.
In fibrotic conditions involving the kidney (62), lung (63) and skin (64) , pericytes have been directly implicated in myofibroblast activation and in deposition of collagenous matrix. Moreover, stimulation of pericytes with growth factors (such as PDGF-BB) has been suggested to induce pericyte-fibroblast transition in tumors (65) and in experimental models of retinopathy (66) .
However, evidence implicating pericytes in activation of fibrogenic pathways in the heart is lacking. Recent studies using robust lineage-tracing approaches suggest that resident fibroblast populations account for the expansion of myofibroblasts in the infarcted heart (67). Whether pericytes also contribute to cardiac fibrosis by undergoing conversion to myofibroblast-like cells remains controversial. Descriptive studies using pericytereporter mice suggested that, although myocardial infarction triggers expansion of a nestin-negative, NG2+ pericyte population, these cells did not exhibit collagen immunoreactivity (23) . The finding was interpreted as suggestive of the absence of a role for pericytes in cardiac fibrosis. However, considering the challenges associated with the detection of collagen expression in tissue sections, the possibility that following injury pericyte-derived cells may no longer express canonical pericyte markers, and the possibility of fibrogenic effects of the pericytes that may be independent of collagen synthesis, these observations do not exclude a crucial role of pericytes in myocardial fibrosis. On the other hand, Kramann et al. found that a large number of myofibroblasts in remodeling and infarcted hearts are derived from Gli1+ 'pericytes' (8) . The notion that pericytes may convert to myofibroblasts was also challenged by a study using lineage tracing of Tbx18+ 'pericytes', which demonstrated that these cells maintain their identity in pressure-overloaded hearts and do not significantly contribute to other lineages (68) . Clearly, the lack of uniform criteria and reliable markers for defining pericytes contributes to the confusion regarding their role in myocardial fibrosis.
Pericytes during the maturation phase of cardiac repair
During the maturation phase of infarct healing, suppression of fibrogenic responses, microvessel maturation and extracellular matrix crosslinking result in the formation of a stable scar and prevent the expansion of fibrosis (39, 69) . Mural cells (both pericytes and vascular smooth muscle cells) play a central role in vascular maturation, by coating infarct neovessels (70, 71) , thus stabilizing the microvasculature of the scar and attenuating inflammation. Antibody inhibition experiments in a mouse model of reperfused myocardial infarction demonstrated that PDGF-BB/PDGFRβ signaling plays a crucial role in scar maturation (70) . Disruption of PDGFRβ signaling perturbed coating of neovessels with mural cells and prolonged hemorrhagic and inflammatory changes in the healing infarct (70) . 
Pericytes as therapeutic targets in myocardial infarction
The absence of robust data on the role of endogenous pericytes greatly limits design of therapeutic approaches targeting these cells in infarcted and remodeling hearts. Most of the evidence suggesting important roles of pericytes in inflammation and fibrosis following myocardial infarction is based on associative data. Documentation of pericyte-specific effects in vivo is particularly challenging; thus, therapeutic targeting of endogenous pericyte actions is heavily based on speculation. Considering their potential role in regulating microvascular function, inhibition of pericyte constriction has been suggested as a promising strategy for protection of the ischemic and reperfused myocardium from 'no-reflow' (22, 57) . Whether approaches targeting endogenous pericyte-mediated actions may protect from adverse post-infarction remodeling restrain inflammation or attenuate fibrosis remains unknown.
Considering their role in angiogenesis, microvascular function, regulation of inflammation and growth factor expression profile, cell therapy with pericytes has been suggested as an attractive strategy to improve repair of the infarcted heart. Experimental studies have suggested that intramyocardial delivery of pericytes may protect the infarcted heart from adverse remodeling by exerting angiogenic and anti-apoptotic actions (72, 73, 74) through paracrine effects on cardiomyocytes, fibroblasts and vascular cells. In a mouse model of myocardial infarction, transplantation of saphenous vein-derived pericytes into the peri-infarct zone attenuated adverse remodeling and improved systolic dysfunction, by secreting angiogenic mediators (such as VEGF and angiopoietin-1) and by releasing protective microRNAs (75) . Pericyte-derived miR-132 was identified a key cardioprotective factor that improved cardiac function following infarction, increasing angiogenesis and attenuating fibrosis (75) . Studies in large animal models have provided additional support to the beneficial effects of pericyte cell therapy following infarction. In a blind, randomized placebocontrolled study in a swine model of reperfused myocardial infarction, transplantation of human adventitial pericytes improved capillary dysfunction and reduced fibrosis (76) . However, these presumably beneficial cell biological actions of pericytes were not associated with any effects on myocardial function. It has also been suggested that human myocardial pericytes, may serve as multipotent precursors and may have limited cardiomyogenic potential (19) . However, robust documentation of pericyte-driven remuscularization in vivo is lacking.
Conclusions
Despite their abundance and their potential significance in regulating a wide range of functions, including microvascular permeability, angiogenesis, inflammation, repair, and fibrosis, cardiac pericytes have been largely ignored by the cardiovascular community. There is an urgent need for studies systematically characterizing cardiac pericyte populations, identifying subsets with distinct functional properties and exploring the role of pericyte-mediated actions in cardiac injury, repair and remodeling.
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